-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cardiovascular disease is the main cause of morbidity and mortality in patients with type 2 diabetes
Heart failure (HF) is the first manifestation of the most common cardiovascular disease in T2D.
All scans were performed on a 3.
Therefore, using cardiovascular magnetic resonance imaging (CMR) and 31 phosphate magnetic resonance spectroscopy (31P-MRS), to explore the effect of selective SGLT2i empagliflozin on myocardial energetics, cell volume, function and perfusion
Results: Enpagliflozin treatment significantly improved the PCr/ATP ratio (1.
Table 1 Changes of clinical parameters after empagliflozin treatment
Table 1 Changes of clinical parameters after empagliflozin treatmentTable 2 Changes in CMR results after empagliflozin treatment
Table 2 Changes in CMR results after empagliflozin treatmentFigure 1 Comparison of the ratio of myocardial creatine phosphate to ATP (PCr/ATP) between patients with type 2 diabetes and the control group at baseline and the change of PCr/ATP before and after 12 weeks of treatment with empagliflozin
Figure 1 Comparison of the ratio of myocardial creatine phosphate to ATP (PCr/ATP) between patients with type 2 diabetes and the control group at baseline and the change of PCr/ATP before and after 12 weeks of treatment with empagliflozin
Figure 2 compares the left ventricular ejection fraction (LVEF) of patients with type 2 diabetes and the control group under the basal state, and the changes of left ventricular ejection fraction (LVEF) before and after 12 weeks of treatment
Figure 2 compares the left ventricular ejection fraction (LVEF) of patients with type 2 diabetes and the control group under the basal state, and the changes of left ventricular ejection fraction (LVEF) before and after 12 weeks of treatment
Enpagliflozin improves the state of "heart energy insufficiency", reverses the unfavorable myocardial cell remodeling, and improves heart function, providing a therapeutic opportunity for the prevention or treatment of heart failure in T2D
Original source:
Thirunavukarasu S, Jex N, Chowdhary A,et al.
Empagliflozin Treatment is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.
Leave a message here